Abstract
RB transcriptional corepressor 1 (RB1) is a critical regulatory gene in physiological and pathological processes. Genetic mutation is considered to be the main cause of RB1 inactivation. However, accumulating evidence has shown that not all RB1 dysfunction is triggered by gene mutations, and the additional mechanism underlying RB1 dysfunction remains unclear. Here, we firstly reveal that a CCCTC binding factor (CTCF) mediated intrachromosomal looping served as a regulatory inducer to inactivate RB1. Once the core genomic fragment was deleted by Clustered Regularly Interspaced Short Palindromic Repeats/Cas9 (CRISPR/Cas9), this intrachromosomal looping was disrupted. After the open of chromatin, Enhancer of Zeste Homolog 2 (EZH2) was released and decreased the level of Tri-Methyl-Histone H3 Lys27 (H3K27me3) at the RB1 promoter, which substantially restored the expression of RB protein (pRB) and inhibited tumorigenesis. In addition, targeted correction of abnormal RB1 looping using the small-molecule compound GSK503 efficiently restored RB1 transcription and suppressed tumorigenesis. Our study reveals an alternative transcriptional mechanism underlying RB1 dysfunction independent of gene mutation, and advancing the discovery of potential therapeutic chemicals based on aberrant chromatin looping.
Similar content being viewed by others
Introduction
RB transcriptional corepressor 1 (RB1) was the first tumor suppressor gene to be found in 19711. Its encoded protein has been proven to have a regulatory role in cell cycle transition, chromosome stability, and cellular metabolism2. Dysfunction of the RB1 gene directly causes various pathological processes, including developmental deficit, immunological microenvironment disorder, and childhood cancer3. Genetic mutations were demonstrated to be the main reason for RB1 inactivation4. According to the Retinoblastoma Gene Mutation Database (RBGMdb), a total of 3393 variants of RB1 have been reported so far. However, with the increasing number of patient genomes being sequenced, ever-increasing evidence has shown that not all RB1 dysfunction patients undergo RB1 genetic mutation5. A report has revealed that many retinoblastoma patients do not have any RB1 exon mutation, and from the point of view of the whole genome, the very few genetic mutations found may not be enough to induce tumorigenesis6. In addition, a family study of multiple myeloma did not detect any deletion of the RB1 locus, which is frequently deleted in patients with multiple myeloma7. These studies raised the possibility that additional causes beyond traditional genetic mutations induce RB1 dysfunction to mediate pathological processes.
Considering these matters as a whole, there is the fundamental fact that the human genome does not exist as a linear entity. The string of nucleotides is wrapped around histones and organized in three-dimensional (3D) space8. It is now clear that the process of gene transcriptional regulation is highly orchestrated by the 3D structure of chromosomes9. On the one hand, the formation of chromosomal looping between gene promoter and enhancer could activate gene transcription by recruiting the transcriptional activator10. On the other hand, chromosomal looping could also inhibit gene expression by recruiting transcriptional repressor11. Thus, the important function of chromosomal looping in regulating gene transcription was always illustrated in a cell-specific pattern12,13,14. We have highlighted the importance of the intrachromosomal loop as a critical epigenetic barrier in cell reprogramming and maintenance of genomic imprinting15,16. In addition, abnormal chromatin interactions have also been found to regulate the transcription of PDGFRA, MYC, and FOXA1 genes in the tumorigenesis of glioma, acute myelogenous leukemia, and prostate cancer, respectively17,18,19. However, the role of 3D chromosome structure in RB1 dysfunction remains an open question.
In this work, we hypothesized whether chromatin loops might have direct influence in RB1 dysfunction and tumorigenesis. We revealed that the formation of a special chromosomal loop at the RB1 locus was an alternative regulatory inducer of RB1 dysfunction. In addition, we demonstrated that the small-molecule compound GSK503 efficiently restored pRB expression and suppressed tumorigenesis via targeted correction of abnormal RB1 chromatin looping. These results suggested an alternative transcriptional mechanism underlying RB1 dysfunction independent of gene mutation, and discovered efficient chemical compounds by targeting aberrant chromatin looping, thereby providing an alternative avenue for exploring gene dysfunction without mutation, and advancing the discovery of therapeutic chemicals based on chromatin looping.
Results
A functional intrachromosomal looping at RB1 locus
We chose two cell lines, including the retinoblastoma cell line RB44 (Supplementary Data 1) and the human multiple myeloma cell line IM920 (Cancer Cell Line Encyclopedia, CCLE, https://sites.broadinstitute.org/ccle, COSMIC ID: 753563), as the non-mutation model of RB1 dysfunction. As expected, RB44 and IM9 cells showed minimal expression of pRB, and sequencing of all RB1 exons did not detect any mutations (Fig. 1A, Supplementary Table 1), which allowed us to explore the cause of RB1 inactivation without interference from genetic mutations. According to the peaks of protein binding (CTCF, H3K27me3, and H3K4me3) in UCSC genome browser (Supplementary Fig. 1), we designed 3C assay to examine chromatin interaction across the entire RB1 locus in 13q14. Interestingly, the quantitative results showed that the RB1 promoter region (site E5) interacted frequently with a chromatin region of the RB1 intron (site E7) in RB44 cells (Fig. 1B; Fig. 1C, lanes 2–3), while this chromatin loop was rarely detected in normal RPE cells (Fig. 1B; Fig. 1C, lanes 4–5). Although we also found additional chromatin loop in HDF (human fibroblasts) control cells in intron 17 adjacent to exon 18 of the RB1 gene, but not in RB44 cells and retinoblastoma-specific RPE control cells (Supplementary Fig. 2), we thus focused on the E5-E7 looping. DNA sequencing verified the existence of this E5-E7 loop between the RB1 promoter (RB1-P, site E5) and site E7 (~25.8 kb downstream of the RB1 transcriptional start site (TSS) and ~24 kb downstream of E5 site) (Fig. 1D). Similar to RB44, this chromatin loop was also found in IM9 cells (Fig. 1E, lane 3). To address the transcriptional activity of the E7 DNA fragment, we cloned a 1.2-kb fragment encompassing the E7 site into a dual luciferase reporter gene system (Fig. 1F). As shown in Fig. 1G, the 1.2-kb RB1-S DNA fragment significantly reduced luciferase activity, while negative control with random fragment and mock control with empty vector did not change the luciferase activity. These results showed that E7 region might function as a potential gene suppressor and the RB1-P-S chromatin loop could be a regulatory factor that induces RB1 dysfunction in tumors.
Interruption of chromosomal looping suppresses tumorigenesis
To investigate the role of the RB1-P-S loop in RB1 dysfunction and tumorigenesis, we then deleted the RB1-S region using the CRISPR/Cas9 system (Fig. 2A). As shown in Fig. 2B, RB1-S was completely deleted from the genome, and we further verified this deletion by sequencing (Fig. 2C, Supplementary Table 4). Next, we found that the RB1-P-S loop was not detected with primers inside (E7) or outside (E7F and E7R) the deleted region in the RB1-S-deleted cells (Fig. 2D, lanes 3–5), whereas it was detected in the non-RB1-S-deleted cells (Fig. 2D, lane 2; Supplementary Fig. 2). More importantly, we observed that pRB expression at the protein level was restored in the RB1-S-deleted cells (Fig. 2E). These data showed that a lack of the RB1-P-S loop was required for RB1 activation. We then asked whether the abolishment of the RB1-P-S loop was beneficial to tumor suppression. We carried out in vitro cell proliferation assays and in vivo orthotropic xenograft experiments. As expected, cell proliferation was significantly reduced after the disruption of the RB1-P-S loop (Fig. 2F, G). In the orthotopic xenograft model of nude mice, we noticed that the lack of the RB1-P-S loop resulted in a significant reduction in tumor volume compared to that of the wild-type mice (Fig. 2H). By weighing the eyeball tissue, we then found that the RB1-S-deleted group showed an ~50% decrease in tumor weight compared with the wild-type group (Fig. 2I). In xenograft tissues, we confirmed that the RB1-P-S loop was not detected in the RB1-S-deleted groups (Fig. 2J). Taken together, these results demonstrated that the RB1-P-S loop was a potential regulatory target that induced RB1 dysfunction and triggered tumorigenesis.
CTCF-PRC2 complex is involved in the chromosomal looping at RB1 locus
Next, we tried to identify a suitable molecular compound for targeted disruption of the RB1-P-S loop and reactivation of the RB1 gene. One possible strategy was to unlock the RB1-P-S loop by determining the core modified factors. We then examined the core factors for organizing the RB1-P-S chromatin loop. CTCF participates in the formation of chromatin loop by directional binding to CTCF binding sites (CBSs) by its 11 zinc fingers21,22,23. We firstly analyzed the location and orientation of CBSs in the E5 promoter region and E7 silencer region, respectively. With bioinformatic program21, we found that six forward CBSs were located in the E5 region and other five reverse CBSs located in the E7 region (Supplementary Fig. 3). Next, we found that CTCF could directly bind to the promoter and suppressor of RB1 (Fig. 3A, first panel, lanes 8 and 13). Since CTCF could contribute to the formation of chromosomal looping by interacting with Cohesin14,24, we then focused on the SMC1, a core protein of Cohesin complex. To further determine whether SMC1 was involved in the formation of RB1-P-S looping, we examined the formation of RB1-P-S looping by silencing of SMC1 (Supplementary Table 4). After SMC1 knockdown (Supplementary Fig. 4a, b), the formation of RB1-P-S looping was not changed (Supplementary Fig. 4c, lanes 3–4). These data suggested that SMC1 was not involved in the formation of RB1-P-S loop.
Given the fact that CTCF has been found to interact with PRC2 complex, which could regulate trimethylation level of H3K27 (H3K27me3). We firstly focused on the level of H3K27me3 at the RB1 promoter. We found a stronger signal of the level of H3K27me3 at the RB1 promoter in tumor cells (Fig. 3A, first panel, lane 3). After RB1-S deletion and RB1-P-S loop disruption, chromatin immunoprecipitation (ChIP) data showed that the H3K27me3 level of the RB1 promoter was markedly decreased (Fig. 3A, second panel, lane 3). We further showed the similar results by using ChIP with quantitative real-time PCR (ChIP-qPCR) (Fig. 3B). To verify these results, we used a tissue chip containing 28 retinoblastoma tissues and 12 normal eye controls, and we found a prominent increase of H3K27me3 level in retinoblastoma tissues compared with normal eye tissues (Fig. 3C). Immunofluorescence assays confirmed the strong staining of H3K27me3 in retinoblastoma tissues (Fig. 3D). These data showed that the decrease of H3K27me3 modification at RB1 promoter was caused by interruption of RB1-P-S chromatin loop. Since the EZH2 protein, a core component of the PRC2 complex, has been shown to control the level of H3K27me325, we next focused on EZH2 binding at the RB1 promoter. Similarly, we found that deletion of the RB1-S region abolished EZH2 binding at the RB1 promoter in RB1-S-deleted cells compared to wild-type tumor cells (Fig. 3A, second panel, lane 2). Given the above results, it raised a possibility that inhibition of EZH2 might reactivate the pRB expression by the decrease of H3K27me3 level at RB1 promoter through using EZH2 inhibitor.
Silencing of CTCF abolishes the chromosomal looping and reactivates pRB expression
To determine the critical role of CTCF in orchestrating the intrachromosomal looping at RB1 locus, we knocked down CTCF in RB1 non-mutation cells by using conventional shRNA method. As expected, we found that the CTCF expression was significantly reduced in real-time PCR assay (Fig. 4A). Moreover, western-blot assay further confirmed that the protein level of CTCF was remarkably decreased as compared to control (Fig. 4B, lanes 2–3). Next, 3 C assay showed that silencing of CTCF abolished the RB1-P-S intrachromosomal looping between RB1 promoter and suppressor (Fig. 4C, lanes 3–4; Fig. 4D). After CTCF knockdown, the ChIP assay also showed that the binding of EZH2 to the RB1 promoter was decreased (Fig. 4E, lane 1), which led to a decrease in H3K27me3 in the RB1 promoter (Fig. 4F). To further determine whether this intrachromosomal looping was responsible for RB1 silencing, we detected the expression level of RB1 in CTCF silencing group. As expected, the expression of pRB was significantly reactivated once CTCF was silenced (Fig. 4G, H). These data showed that the abolishment of the abnormal intrachromosomal loop was critical cause for reactivating of pRB expression.
GSK503 interrupts the chromosomal looping and restores pRB expression in RB1 non-mutated tumor cells
To test this hypothesis, we carried out a preclinical study using an EZH2 inhibitor, the leading molecular compound GSK503, which is a small chemically optimized compound that efficiently targets the SET domain of EZH2 and exhibits favorable pharmacokinetics in mice. EZH2 inhibitor has been reported to be efficient efficacy in RB1-mutational Y79 and Weri retinoblastoma cells26. We next treated RB1 non-mutated tumor cells with 10 µM GSK503 for 72 h and found that the binding of EZH2 to the RB1 promoter was abolished, which led to a decrease in H3K27me3 in the RB1 promoter (Fig. 5A, B). As expected, GSK503 caused the targeted disruption of the RB1-P-S loop between the RB1 promoter and suppressor (Fig. 5C), and none of the treatment groups retained the RB1-P-S loop (Fig. 5D). Most importantly, after GSK503 treatment, the protein expression of RB1 was significantly restored (Fig. 5E, F). These results suggested that GSK503 was an efficient chemical compound to realize the targeted disruption of the CTCF-EZH2 mediating chromatin loop by inhibiting EZH2 activity and thereby to reactivate the RB1 gene in tumor cells without RB1-mutations.
GSK503 obtains efficient therapeutical effect in RB1 non-mutated tumors
Next, we examined the role of GSK503 in RB1 non-mutated tumor cells. As expected, the cell proliferation assay showed that GSK503 significantly reduced tumor proliferation and colony formation in both RB44 and IM9 tumor cells in vitro (Fig. 6a–c). Next, we tried to verify this outcome in vivo. An orthotopic xenograft model of retinoblastoma cells was used. After the tumors formed one week after orthotopic transplantation, a daily subconjunctival dose of 3 µl of 10 µM GSK503 was administered for 7 days. The mice treated with GSK503 exhibited a significant reduction in tumor size. H&E staining also showed that the intraocular structure in the non-GSK503-treated group was destroyed, while tumor proliferation in the GSK503-treated group was suppressed and the intraocular structure was retained (Fig. 6d). We also noticed that GSK503 significantly reduced the tumor weight (Fig. 6e). A heterotopic transplantation model was used for IM9 cells. Subcutaneous injection of 3 µl of 10 µM GSK503 was carried out for 7 days once the tumor formed, and the GSK503-treated group showed significant tumor suppression (Fig. 6f). By weighing the tumor tissues, we observed that GSK503 significantly reduced the tumor weight (Fig. 6g). Together, these results reveal that GSK503 has efficient therapeutic efficacy in restored pRB expression and suppressed tumorigenesis.
Discussion
As a major factor influencing gene dysfunction, genetic mutation is generally considered to be the trigger of gene dysfunction27. However, with the development of high-throughput sequencing technology, increasing evidence has shown that genetic mutations are not the only cause of gene dysfunction6. The occurrence of acute senescence is mediated by non-mutated HMGA2 dysfunction28. BRCA1 is an important tumor suppressor, and 35.3% of BRCA1 dysfunction in ovarian cancer was found to be unrelated to germline or somatic mutations29. Dysfunction of TP53 without genetic mutations in tumorigenesis, cell cycle arrest, apoptosis, and senescence has also been reported30. Gene mutation was found to be the major cause of biallelic inactivation of RB131; however, the additional mechanism underlying RB1 dysfunction remains unknown32. In this study, to the best of our knowledge, we demonstrate for the first time that the formation of a special intrachromosomal loop at the RB1 locus is an alternative cause of RB1 dysfunction. When the RB1-P-S chromosomal loop between the RB1 promoter and suppressor was established, EZH2 was then recruited and increased the level of H3K27me3 at the RB1 promoter, thereby inhibiting pRB expression and leading to tumorigenesis (Fig. 7).
Since RB1 dysfunction without genetic mutation often induces the occurrence of disease by regulating various pathological processes33, our finding of the RB1 chromosomal loop ushers in an interesting era of exploring the mechanisms of RB1 dysfunction in these additional pathological processes. Most importantly, the dysfunction of many important physiological and pathological genes, including PP2A and FOXG1, is not always triggered by genetic mutations34,35. This study is likely to open a avenue for discovering the mechanisms underlying gene dysfunction without genetic mutations. It should be noted that a retroposon involved in the imprinting of the RB1 gene in close proximity to our deleted region36. It raise an interesting possibility that the retroposon transcription may involve in RB1 gene activation by reducing compaction of the nucleosomes at RB1 promoter. Thus, it would be of great interest to explore this alternative mechanism of RB1 activation.
It should be emphasized that this an alternative epigenetic model of pRB restoration is shown in non-RB1-mutational tumor cells in our study. However, it is unclear whether a similar epigenetic model is occurred in RB1-mutational tumor cells, and it would be of great interest to further explore the epigenetic possibility of RB1 activation in RB1-mutational tumor cells. An alternative explanation of pRB epigenetic restoration in non-RB1-mutational tumor cells is that the restoration of pRB expression is likely to require two-layer gene regulation, including firstly correct chromosomal looping for epigenetically RB1 activation and secondly correct RB1 exon sequences for genetically accurate pRB translation. Therefore, the abolishment of aberrant chromosomal looping was enough to make sure the restoration of pRB expression, because correct sequences of RB1 exons in non-RB1-mutational tumor cells would not result in inaccurate pRB translation. Moreover, in terms of epigenetics of RB1 regulation in tumors, CTCF firstly orchestrates a promoter-enhancer chromosomal looping and then recruits EZH2 to change H3K27me3 modification, which subsequently co-establish the regulatory pathway and suppress the pRB expression. However, either the interruption of RB1-P-S looping or the abolishment of EZH2 by GSK503 will destroy the epigenetic pathway of pRB suppression and reactivate pRB expression. Further studies should focus on the identification of unknown factors involved in this epigenetic regulatory process of pRB expression.
As a key part of epigenetic studies, abnormal chromosomal conformation has been proven to play an important role in several physiological and pathological processes37. Our previous study highlighted the importance of the intrachromosomal loop as a critical epigenetic barrier in cell reprogramming16. The formation of an abnormal chromatin loop activated the oncogene PDGFRA and triggered tumorigenesis17. Effective targeted correction of these abnormal chromatin loops is an open question and a research hotspot. Most current studies focus on deleting abnormal genomic fragments or ectopically expressing foreign factors38; however, these classic experimental technologies in the laboratory have obvious limitations for further industrial application. Finding suitable leading small-molecule compounds for chromatin correction is an efficient and promising way to overcome these barriers6. This is, to our knowledge, the first study showed that the small-molecule compound GSK503 efficiently restored pRB expression and suppressed tumorigenesis in non-RB1-mutational tumor cells. Although targeted correction of abnormal RB1 chromatin looping is one of the causes in the GSK503 mediating tumorigenesis suppression, we cannot eliminate other genetic or epigenetic causes. Thus, it would be of great interest to focus on the identification of other affects to better understand the role of EZH2 inhibitor in suppressing tumorigenesis. Most importantly, many physiological and pathological genes are regulated by alteration of chromosomal conformation. This finding will advance the discovery of useful chemical compounds by directing focus to the targeted correction of aberrant chromatin architecture, thereby accelerating the potential industrial and clinical prospects.
Methods
Cell culture
The RB1 non-mutated human retinoblastoma cell line RB44 and human multiple myeloma cell line IM9 were cultured in RPMI-1640 (Gibco, USA) supplemented with 10% certified heat-inactivated fetal bovine serum (FBS; Gibco, USA), penicillin (100 U/ml), and streptomycin (100 μg/ml) at 37 °C in a humidified 5% CO2 atmosphere. The human normal cell lines HDF and RPE were cultured in DMEM (Gibco, USA) supplemented with 10% FBS (Gibco, USA), penicillin (100 U/ml), and streptomycin (100 μg/ml) at 37 °C in a humidified 5% CO2 atmosphere. IM9 and RPE cell lines were purchased from ATCC, RB44 and HDF were primary culture cells in our lab.
RNA isolation and cDNA synthesis
Total RNA was extracted from cultured cells using TRIzol reagent (Sigma-Aldrich). The purified RNA was quantified using a Nanodrop 2000 UV-Vis Spectrophotometer (Thermo Scientific). The same amounts of total RNA were reverse transcribed into cDNA using the PrimeScript RT reagent Kit (TaKaRa Biotechnology).
qRT-PCR
We validated the expression level of RB1 by quantitative real-time RT-PCR (qRT-PCR). Expression levels were validated by real-time PCR using an ABI Prism 7500 (Applied Biosystems) using Power SYBR Green PCR Master Mix (Applied Biosystems) with the following protocol: an initial 10 min incubation at 95 °C followed by 40 cycles of 95 °C for 15 s and 60 °C for 30 s. All of the genes were normalized to the control gene glyceraldehyde phosphate dehydrogenase (GAPDH).
Chromosome conformation capture (3C)
1.0 × 107 cells were cross-linked with 2% formaldehyde and quenched with 0.125 M glycine. The cells were lysed with cell lysis buffer (10 mM Tris [pH 8.0], 10 mM NaCl, 0.2% NP-40, and protease inhibitors), and the nuclei were collected. The nuclei were resuspended in 1× restriction enzyme buffer in the presence of 0.3% sodium dodecyl sulfate (SDS) and incubated at 37 °C for 1 h. Triton X-100 was then added to a final concentration of 1.8% to sequester the SDS. An aliquot of nuclei (2 × 106) was digested with 800 U of the restriction enzyme EcoRI at 37 °C overnight. Then, 1.6% SDS was added, and the mixture was incubated at 65 °C for 20 min to stop the reaction. Chromatin DNA was diluted with T4 ligation buffer, and 2 μg DNA was ligated with 4000 U of T4 DNA ligase (Takara, Japan) at 16 °C for 4 h (final DNA concentration, 2.5 μg/ml). After treatment with 10 mg/ml proteinase K at 65 °C overnight to reverse the cross-links and with 0.4 μg/ml RNase A for 30 min at 37 °C, DNA was extracted with phenol-chloroform, ethanol precipitated, and used for PCR amplification of the ligated DNA products. We used nested PCR to achieve a final product of 100–350 bp in length for further analysis. The products of first PCR reaction were diluted to 1/100 to be the template of the second PCR reaction. First and second PCR cycles: an initial 2 min incubation at 95 °C followed by 30 cycles of 95 °C for 15 s, 65 °C for 30 s, and 72 °C for 30 s. The detailed PCR primers were shown in Supplementary Tables 2, 3.
Luciferase assay
Site B4 and site B8 were amplified from genomic DNA using primers incorporating restriction enzyme sites (HindIII–XhoI) and then cloned into the HindIII–XhoI sites upstream of the promoter-Luc transcriptional unit. Luciferase assays were performed in 24-well white plates using the Luciferase Assay System (Promega, USA) according to the manufacturer’s protocol.
ChIP
The ChIP assay was performed as previously described. The cells were fixed with 1% formaldehyde and centrifuged, and the pellets were resuspended in ChIP lysis buffer (50 mM Tris-HCl [pH 8.0]), incubated for 10 min on ice, and then sonicated (10 s on, 15 s off, output 30%, 4 min). The supernatant was collected into a new tube, and 5 mg of antibody (CTCF 1:200, EZH2 1:200, and H3K27 1:200 [Cell Signaling Technology], IgG 1:200 [Abcam]) was added. The mixture was then incubated overnight at 4 °C, and 60 ml of Pure Proteome Protein A and Protein G Magnetic Beads (Millipore) was used to pull down the DNA-protein-antibody complexes at 4 °C for 6 h. The DNA complexes were eluted using 0.2 M glycine. After crosslink reversal and purification, the samples were ready for PCR. Primers: L1: tcttcctcagacgtttccacgg, L2: tagaaaatgttagacacttgctggc, L3: actcccagaccacgagactt, L4: tcctgaggaggtaccaagaca.
Western blot
Cells were harvested at the indicated times and rinsed twice with PBS. Cell extracts were prepared with lysis buffer and centrifuged at 12,000 rpm for 30 min at 4 °C. Protein samples were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) in 7.5% (wt/vol) polyacrylamide gels and transferred to polyvinylidene fluoride membranes. After blocking with 5% BSA for 1 h at room temperature, the membrane was incubated with 2.5 μg/ml antibody in 5% BSA overnight at 4 °C. The membrane was then incubated with a secondary antibody conjugated to a fluorescent tag (Invitrogen). The band signals were visualized and quantified using the Odyssey Infrared Imaging System (LI-COR, USA). The following antibodies were used: anti-pRB 1:1000 (ab226979, Abcam, USA), anti-CTCF 1:500 (ab128873, Abcam, USA), anti-H3K27me3 1:500 (ab6002, Abcam, USA), and β-actin 1:5000 (A5316, Sigma-Aldrich).
CRISPR/Cas9-mediated deletions
Four small gRNAs (sgRNAs) were cloned separately into lenti-Guide-Puro plasmids. To delete the 1.4 kb RB1-S region from the genome, RB44 cells were transfected with plasmids containing gRNAs (and Cas9) targeting the left and right side of the region to be deleted. Colonies were derived from single cells and tested for the loss of the targeted region. The control group was transfected with gRNA-empty vector using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s instructions.
Immunofluorescence
The immunofluorescence assay was performed as previously described39. Human retinoblastoma tissues and normal eye tissues were incubated with anti-H3K27me3 (AB6002, Abcam, USA) antibodies at 4 °C overnight. Thereafter, the slides were incubated with the appropriate secondary antibodies for 30 min, and nuclei were counterstained with DAPI (Sigma-Aldrich) for 1 h. Digital images were obtained with a confocal microscope. Relative level of H3K27me3 was determined by comparing the fluorescence intensity of the target antibody with that of DAPI.
CCK8 cell viability assay
For CCK8 assay, cells were seeded into a flat-bottomed 96-well culture plate at 2000 cells per well with 100 μl culture medium. In brief, 10 μl of CCK8 (Dojindo, Japan) solution was added to each well. The samples were incubated for 4 h; then the absorbance was measured at 450 nm in a microplate reader (Varioskan Flash; Thermo, USA) for 4 consecutive days.
Plate colony formation assay
A plate colony formation assay was performed in six-well plates. A total of 1000 cells were suspended in 2.0 ml of complete medium and seeded into each well. The cells were cultured with complete medium for 10 days. For quantification, the colonies grown in plates were stained with 1% crystal violet and then photographed.
Tumor xenograft model and in nude mice
Animal protocols were approved by the Animal Care and Use Committee at Shanghai Jiao Tong Medical College. Male 3-week-old nude mice were deeply anesthetized. To build orthotopic xenograft models, RB44 and RB44-RB1-S-deletion cells in a 4 μl sterile saline solution were injected into the sub retina and vitreous chamber of each eye through the sclera using a Hamilton syringe. After the injection, the eyes were treated with antibiotic eye drops. To build subcutaneous xenograft models, IM9 cells in a 0.2 ml volume of sterile saline solution were subcutaneously injected into the right flank. All mice were cervically dislocated 49 days after implantation for the tumor formation analysis.
Statistics and reproducibility
All of the experiments were performed in triplicate, and the data were expressed as the mean ± standard deviation (SD, Error bars). The comparative threshold cycle method was applied in the quantitative real-time PCR assay according to the ΔΔ threshold cycle method. The differences between two groups were analyzed with the unpaired two-sided Student’s t-test. p value of less than 0.01 or 0.001 was considered statistically significant and is indicated with double or triplicate asterisks, as described in the figure legends.
Reporting summary
Further information on research design is available in the Nature Research Reporting Summary linked to this article.
Data availability
All uncropped and unedited blot/gel images are available in Supplementary Fig. 5. All source data of all RB1 exons in RB44 cell is available in Supplementary Data 1, these data show all original sequences of 27 exons of RB1 gene in RB44 cells for aligning with existed RB1 NCBI Reference Sequence: NM_000321.3. All source data underlying the graphs and charts presented in the main figures are available in Supplementary Data 2.
References
Knudson, A. G. Jr. Mutation and cancer: statistical study of retinoblastoma. Proc. Natl Acad. Sci. USA 68, 820–823 (1971).
Bertoli, C., Skotheim, J. M. & de Bruin, R. A. Control of cell cycle transcription during G1 and S phases. Nat. Rev. Mol. Cell Biol. 14, 518–528 (2013).
Walter, D. M. et al. RB constrains lineage fidelity and multiple stages of tumour progression and metastasis. Nature 569, 423–427 (2019).
Dimaras, H. et al. Retinoblastoma. Nat. Rev. Dis. Prim. 1, 15021 (2015).
Rushlow, D. E. et al. Characterisation of retinoblastomas without RB1 mutations: genomic, gene expression, and clinical studies. Lancet Oncol. 14, 327–334 (2013).
Zhang, J. et al. A novel retinoblastoma therapy from genomic and epigenetic analyses. Nature 481, 329–334 (2012).
Lynch, H. T., Sanger, W. G., Pirruccello, S., Quinn-Laquer, B. & Weisenburger, D. D. Familial multiple myeloma: a family study and review of the literature. J. Natl Cancer Inst. 93, 1479–1483 (2001).
Jin, F. et al. A high-resolution map of the three-dimensional chromatin interactome in human cells. Nature 503, 290–294 (2013).
Hughes, J. R. et al. Analysis of hundreds of cis-regulatory landscapes at high resolution in a single, high-throughput experiment. Nat. Genet. 46, 205–212 (2014).
Kagey, M. H. et al. Mediator and cohesin connect gene expression and chromatin architecture. Nature 467, 430–435 (2010).
Zhang, H. et al. Interruption of intrachromosomal looping by CCCTC binding factor decoy proteins abrogates genomic imprinting of human insulin-like growth factor II. J. Cell Biol. 193, 475–487 (2011).
Finn, E. H. et al. Extensive heterogeneity and intrinsic variation in spatial genome organization. Cell 176, 1502–1515 e1510 (2019).
Rao, S. S. P. et al. Cohesin loss eliminates all loop domains. Cell 171, 305–320 e324 (2017).
Hansen, A. S., Pustova, I., Cattoglio, C., Tjian, R. & Darzacq, X. CTCF and cohesin regulate chromatin loop stability with distinct dynamics. Elife 6, e25776 (2017).
Zhang, H. et al. Long noncoding RNA-mediated intrachromosomal interactions promote imprinting at the Kcnq1 locus. J. Cell Biol. 204, 61–75 (2014).
Zhang, H. et al. Intrachromosomal looping is required for activation of endogenous pluripotency genes during reprogramming. Cell Stem Cell 13, 30–35 (2013).
Flavahan, W. A. et al. Insulator dysfunction and oncogene activation in IDH mutant gliomas. Nature 529, 110–114 (2016).
Wan, L. et al. ENL links histone acetylation to oncogenic gene expression in acute myeloid leukaemia. Nature 543, 265–269 (2017).
Parolia, A. et al. Distinct structural classes of activating FOXA1 alterations in advanced prostate cancer. Nature 571, 413–418 (2019).
Weide, R. et al. Altered expression of the retinoblastoma gene product in human high grade non-Hodgkin’s lymphomas. Leukemia 8, 97–101 (1994).
He, X. L., Li, J. H. & Wu, Q. [Combinatorial CRISPR inversions of CTCF sites in HOXD cluster reveal complex insulator function]. Yi Chuan 43, 758–774 (2021).
Yin, M. et al. Molecular mechanism of directional CTCF recognition of a diverse range of genomic sites. Cell Res. 27, 1365–1377 (2017).
Guo, Y. et al. CRISPR inversion of CTCF sites alters genome topology and enhancer/promoter function. Cell 162, 900–910 (2015).
Rubio, E. D. et al. CTCF physically links cohesin to chromatin. Proc. Natl Acad. Sci. USA 105, 8309–8314 (2008).
Margueron, R. & Reinberg, D. The Polycomb complex PRC2 and its mark in life. Nature 469, 343–349 (2011).
Khan, M. et al. Characterization and pharmacologic targeting of EZH2, a fetal retinal protein and epigenetic regulator, in human retinoblastoma. Lab. Invest. 95, 1278–1290 (2015).
Lynch, M. et al. Genetic drift, selection and the evolution of the mutation rate. Nat. Rev. Genet. 17, 704–714 (2016).
Sati, S. et al. 4D genome rewiring during oncogene-induced and replicative senescence. Mol. Cell 78, 522–538 e529 (2020).
Geisler, J. P., Hatterman-Zogg, M. A., Rathe, J. A. & Buller, R. E. Frequency of BRCA1 dysfunction in ovarian cancer. J. Natl Cancer Inst. 94, 61–67 (2002).
Levine, A. J. & Oren, M. The first 30 years of p53: growing ever more complex. Nat. Rev. Cancer 9, 749–758 (2009).
Grobner, S. N. et al. The landscape of genomic alterations across childhood cancers. Nature 555, 321–327 (2018).
Munier, F. L. et al. Conservative management of retinoblastoma: challenging orthodoxy without compromising the state of metastatic grace. “Alive, with good vision and no comorbidity”. Prog. Retin. Eye Res. 73, 100764 (2019).
Hernando, E. et al. Rb inactivation promotes genomic instability by uncoupling cell cycle progression from mitotic control. Nature 430, 797–802 (2004).
Shu, S. et al. Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer. Nature 529, 413–417 (2016).
Won, H. et al. Chromosome conformation elucidates regulatory relationships in developing human brain. Nature 538, 523–527 (2016).
Grothaus, K. et al. Genome-wide methylation analysis of retrocopy-associated CpG islands and their genomic environment. Epigenetics 11, 216–226 (2016).
Jager, R. et al. Capture Hi-C identifies the chromatin interactome of colorectal cancer risk loci. Nat. Commun. 6, 6178 (2015).
Chai, P. et al. Generation of onco-enhancer enhances chromosomal remodeling and accelerates tumorigenesis. Nucleic Acids Res. 48, 12135–12150 (2020).
Yu, J. et al. Histone lactylation drives oncogenesis by facilitating m(6)A reader protein YTHDF2 expression in ocular melanoma. Genome Biol. 22, 85 (2021).
Acknowledgements
This work was supported by the National Key Research and Development Plan (2017YFE0196300), the National Natural Science Foundation of China (Grant 31870748, 81802739), the Shanghai Natural Science Foundation (Grant 22ZR1466100), the ShuGuang Project of Shanghai Municipal Education Commission and Shanghai Education Development Foundation (17SG19), the Shanghai Science and Technology Development Funds (19QA1405100), the Outstanding Yong Medical Scholar of Shanghai Municipal Commission of Health and Family Planning (2017YQ067), and the Outstanding Yong Scholar Grant of Tongji University (PA2019000239), the Startup Funding of Frontier Science Research Center for Stem Cells & Shanghai East Hospital of Tongji University (DFRC2019003). We thank our international partner professor Frenkel Shahar and professor Alik Honigman for their useful assistance and professional suggestions.
Author information
Authors and Affiliations
Contributions
In this report, X.Y.W., T.Y.D., and F.L. designed and performed the experiments and drafted the manuscript; J.Y.F. was responsible for sample collection and data analysis; X.Q.F., R.B.J., and H.Z. discussed, revised, and approved the manuscript. All the authors approved this manuscript.
Corresponding authors
Ethics declarations
Competing interests
The authors declare no competing interests.
Peer review
Peer review information
Communications Biology thanks the anonymous reviewers for their contribution to the peer review of this work. Primary Handling Editor: Eve Rogers.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Wen, X., Ding, T., Li, F. et al. Interruption of aberrant chromatin looping is required for regenerating RB1 function and suppressing tumorigenesis. Commun Biol 5, 1036 (2022). https://doi.org/10.1038/s42003-022-04007-2
Received:
Accepted:
Published:
DOI: https://doi.org/10.1038/s42003-022-04007-2
- Springer Nature Limited